Analysis of influencing factors of medical cost ratio of breast cancer cases treated with chemotherapy and molecular targeted therapy
10.3760/cma.j.cn111325-20211008-00922
- VernacularTitle:乳腺恶性肿瘤化疗和靶向治疗病例的医疗费用倍率影响因素分析
- Author:
Xi SUN
1
;
Haipeng XIA
;
Jianhong WU
Author Information
1. 华中科技大学同济医学院附属同济医院医务处，武汉 430030
- Keywords:
Fees, medical;
Diagnosis-related groups;
Medical expense rate;
High-rate cases;
Influencing factors
- From:
Chinese Journal of Hospital Administration
2022;38(2):106-109
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To understand the medical cost ratio and its influencing factors of breast cancer chemotherapy and molecular targeted therapy in a hospital, for reference for reasonable control of medical cost.Methods:The first page data of all breast cancer chemotherapy and molecular targeted therapy cases in a tertiary hospital from January to June 2021 were selected to extract the data of age, hospitalization expenses, hospitalization time, complications or complications. The influence of each index on the distribution of medical expense ratio was analyzed by single factor analysis and chi-square test was used for comparison between groups.Results:A total of 3 109 cases of chemotherapy and molecular targeted therapy for breast malignant tumors were included, of which very low-rate, low-rate, high-rate and very high-rate accounted for 7.04%(219 cases), 58.32%(1 813 cases), 30.81%(958 cases) and 3.83%(119 cases) respectively. In addition to the way of admission, there were significant differences in the distribution of medical cost rates under different ages, time consumption index, complications or concomitants, admission departments, treatment methods and medical insurance types( P<0.01). Conclusions:There were many factors affecting the medical cost rate of breast malignant tumors. Relevant departments should expand the pilot scope of DRG payment, promote the multi-disciplinary diagnosis and treatment mode of tumors, refine the DRG grouping scheme, to provide standardized and homogeneous diagnosis and treatment services for tumor patients, and reasonably control the excessive growth of medical costs.
